Canine Acute Kidney Injury: Recognition and Management

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Canine Acute Kidney Injury (AKI) is defined by an acute rise in serum creatinine, potentially with oliguria, and is staged using the IRIS AKI grading scheme based on creatinine levels and urine output. Early recognition relies on serial creatinine measurements, urine output quantification, and urine sediment examination.
• Distinguishing AKI from Chronic Kidney Disease (CKD) involves assessing renal size (small/irregular suggests CKD), anemia (disproportionate anemia favors CKD), ultrasound findings (mineralization, cysts suggest CKD), urine concentrating ability (isosthenuria suggests intrinsic renal injury), and response to fluid therapy (AKI improves, CKD does not).
• Common causes of AKI include ischemic injury (hypotension, sepsis) and nephrotoxic injury (NSAIDs, aminoglycosides, ethylene glycol). Pathophysiology involves mitochondrial dysfunction, oxidative stress, endothelial injury, and maladaptive tubular repair that can bridge AKI to CKD.
• Initial diagnostics for suspected AKI include a thorough history, physical examination, complete blood count, serum biochemistry (creatinine, BUN, electrolytes, phosphorus), urinalysis with sediment examination and culture, blood pressure measurement, and abdominal ultrasound.
• Fluid therapy is foundational, aiming for euvolemia with balanced crystalloids (e.g., Lactated Ringer's), avoiding starch-containing colloids. Monitoring includes serial body weight, urine output (target >1 mL/kg/hr), serum creatinine, electrolytes (especially potassium), blood pressure, and acid-base status.
• Management of AKI involves fluid therapy, hemodynamic support, and addressing complications like hyperkalemia and volume overload. Diuretics like furosemide are used for volume management, not to treat the renal injury itself. Nutritional support with adequate protein and phosphorus restriction is crucial, alongside gastrointestinal protection.

Acute kidney injury (AKI) in dogs is a rapid decline in glomerular filtration rate with consequent accumulation of nitrogenous wastes, disruption of fluid and electrolyte balance, and impaired endocrine and excretory function. This article provides a diagnostic framework for early recognition, a staging approach for severity assessment, and a structured management plan for the practicing veterinarian. It assumes familiarity with routine biochemistry, urinalysis, and basic fluid therapy principles, and it does not address chronic kidney disease management or the technical details of renal replacement therapy.

The clinical question this article answers is practical: when a dog presents with azotemia, how does the clinician distinguish AKI from chronic disease, assign a severity stage, identify the underlying cause, and initiate therapy that improves the likelihood of renal recovery? The emphasis throughout is on the first 48 to 72 hours of presentation, when diagnostic and therapeutic decisions exert the greatest influence on outcome.

At a Glance

Pathophysiology of Acute Kidney Injury

The kidney is highly susceptible to ischemic and toxic injury because of its high metabolic demand, dense capillary network, and concentration of filtered toxins in the tubular lumen. The initial insult, whether hemodynamic, nephrotoxic, or inflammatory, triggers a cascade of cellular stress responses that determine whether injury remains reversible or progresses to permanent nephron loss.

Mitochondrial dysfunction is central to this cascade. Damaged mitochondria generate excessive reactive oxygen species, which oxidize cellular lipids, proteins, and DNA. The cell's quality control mechanism, mitophagy, selectively eliminates these dysfunctional organelles. When mitophagy is overwhelmed or impaired, injured tubular epithelial cells undergo apoptosis, pyroptosis, or ferroptosis, each of which amplifies local inflammation and recruits additional immune cells. The interplay between oxidative stress and cell death pathways is a major determinant of the extent of tubular injury, as reviewed in the context of mitochondrial ROS and mitophagy in acute kidney injury by Su and colleagues.

The renal vasculature participates actively in the injury process. Endothelial injury, loss of peritubular capillary integrity, and microvascular shunting reduce oxygen delivery to the already stressed tubular epithelium. In sepsis, the most common AKI syndrome in human intensive care, these microcirculatory changes may occur without frank tubular necrosis, suggesting a functional component that is potentially reversible with early resuscitation. This observation, drawn from the institutional review of acute kidney injury in sepsis by Bellomo and colleagues, has direct relevance to canine practice: a dog with sepsis and azotemia may have minimal histologic damage, and aggressive early hemodynamic support can restore function.

The tubular epithelium's capacity for repair determines long-term outcome. Surviving cells dedifferentiate, proliferate, and migrate to repopulate denuded basement membranes. Maladaptive repair, however, produces growth-arrested cells that persist and drive interstitial fibrosis. This maladaptive response, involving macrophages, pericytes, and the endothelium, is the mechanistic bridge between a single episode of AKI and subsequent chronic kidney disease, as described in the review of acute kidney injury by Zuk and Bonventre. The clinical implication is that even a dog that "recovers" from AKI may carry residual structural damage that predisposes to future decline.

Defining and Recognizing AKI

Consensus definitions of AKI in human medicine rely on two parameters: serum creatinine concentration and urine output. The same logic applies in veterinary medicine, although species-specific staging systems have been adapted. The International Renal Interest Society (IRIS) publishes a staging scheme for canine AKI that grades severity from grade I (non-azotemic but with risk factors or biomarkers of injury) through grade V (requiring renal replacement therapy). Within each grade, the scheme further subclassifies by urine output into non-oliguric, oliguric, and anuric categories, because urine output is a powerful predictor of outcome and directly guides fluid and diuretic therapy.

Early recognition requires more than a single creatinine measurement. A dog with normal baseline renal function can lose a substantial fraction of functional nephrons before serum creatinine rises above the reference interval. Serial measurements that demonstrate a rising trend, even within the reference range, are more informative than a single value. Urine output quantification, ideally by weighing diapers or using a urinary catheter in hospitalized patients, provides complementary information. A falling urine output in the face of adequate perfusion is an early warning sign that precedes creatinine elevation.

The distinction between AKI and chronic kidney disease is not always straightforward. Historical clues such as polyuria, polydipsia, weight loss, and poor hair coat suggest chronicity. Physical examination findings of small irregular kidneys, oral ulceration, and pale mucous membranes support chronic disease. Ultrasonographic changes including reduced corticomedullary distinction, renal mineralization, and cystic lesions point to chronicity. Anemia out of proportion to the degree of azotemia favors chronic disease, although acute blood loss or hemolysis can confound this interpretation. When uncertainty persists, a recheck examination in 48 to 72 hours after fluid therapy often clarifies the picture: a dog with AKI will show improvement in azotemia with appropriate therapy, whereas a dog with end-stage CKD will not.

Causes and Risk Factors

Ischemic injury results from any condition that reduces renal perfusion. Dehydration, hemorrhage, hypovolemic shock, congestive heart failure, and hypotension during anesthesia are common clinical scenarios. Sepsis deserves particular attention because it combines systemic vasodilation, myocardial depression, and microcirculatory dysfunction, each of which compromises renal oxygen delivery. The recognition that septic AKI may be predominantly functional instead of structural reinforces the urgency of early, goal-directed resuscitation.

Nephrotoxic injury arises from a broad range of agents. Nonsteroidal anti-inflammatory drugs reduce renal prostaglandin synthesis, which is critical for maintaining afferent arteriolar vasodilation in the volume-depleted kidney. Aminoglycosides accumulate in proximal tubular cells and cause dose-dependent injury. Ethylene glycol is metabolized to toxic organic acids that cause severe tubular damage and calcium oxalate crystal deposition. Other nephrotoxins encountered in practice include heavy metals, certain chemotherapeutic agents, and some herbal products. The history should specifically probe for recent medication administration, toxin exposure, and access to household chemicals.

Urate metabolism warrants mention in the context of tumor lysis syndrome and other hyperuricemic states. The National Kidney Foundation scientific workshop on hyperuricemia reviewed evidence that elevated serum urate can directly injure the kidney through crystal-dependent and crystal-independent mechanisms. While this is less commonly recognized in dogs than in humans, the clinician should consider urate nephropathy in dogs with severe hyperuricemia, particularly those with portosystemic shunts or genetic predispositions to urate urolithiasis.

The Role of Biomarkers

Serum creatinine and urine output remain the diagnostic standard for AKI, but both have limitations. Creatinine rises slowly after injury, is influenced by muscle mass and hydration status, and does not distinguish between functional and structural injury. This has driven interest in novel biomarkers that detect tubular injury earlier and more specifically.

Interleukin-18 (IL-18) is one such candidate. It is a pro-inflammatory cytokine of the IL-1 family, constitutively present as an inactive precursor in nearly all cells and cleaved by caspase-1 to its active form during inflammation. In the kidney, IL-18 is released into the urine by injured proximal tubular cells, and urinary IL-18 concentrations rise within hours of ischemic injury, well before creatinine elevation. The activity of IL-18 is modulated by a naturally occurring binding protein, and an imbalance between the cytokine and its binding protein may reflect disease severity, as reviewed by Dinarello and colleagues. While IL-18 assays are not yet routine in veterinary practice, the principle that urinary biomarkers can precede creatinine changes is established and informs the direction of clinical research.

Cell cycle arrest biomarkers, including tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein-7, have gained acceptance in human critical care for early AKI detection. These markers reflect tubular cell stress and entry into G1 cell cycle arrest, a protective response that prevents replication of damaged DNA. Their utility in canine medicine is under investigation, and the clinician should interpret any biomarker result in the context of the full clinical picture instead of as a standalone diagnostic test.

Initial Assessment and Diagnostic Sequence

The first encounter with a suspected AKI patient requires a structured sequence that distinguishes prerenal azotemia, intrinsic renal injury, and postrenal obstruction before any therapeutic commitment. Begin with a complete history focusing on recent drug administration, anesthetic events, toxin exposure, trauma, and any episode of hypotension or hypovolemia. Physical examination should prioritize hydration status, mucous membrane color, capillary refill time, heart rate, pulse quality, and abdominal palpation for renal size, shape, and pain. Bladder size and the ability to urinate must be assessed early because a distended, painful bladder with anuria points toward obstruction instead of intrinsic failure.

Baseline laboratory work includes serum creatinine, blood urea nitrogen, symmetric dimethylarginine, electrolytes, calcium, phosphorus, and a complete blood count. Urinalysis with sediment examination is mandatory. Isosthenuria in the face of azotaemia supports intrinsic renal injury, whereas a concentrated urine suggests prerenal azotaemia. Urine sediment may reveal casts, cellular debris, or crystals that narrow the differential. Urine culture should be submitted when pyuria or bacteriuria is present. Blood pressure measurement is essential because hypertension both complicates AKI and may indicate underlying chronic disease. Thoracic radiographs and abdominal ultrasound help exclude urolithiasis, pyelonephritis, neoplasia, and chronic kidney disease with acute decompensation.

The distinction between acute and chronic disease changes management and prognosis. Small, irregular kidneys with poor corticomedullary definition indicate chronicity. Normal-sized or enlarged kidneys with pain suggest acute injury. A history of polyuria and polydipsia preceding the presentation, poor body condition, and nonregenerative anemia all favour chronic kidney disease. When uncertainty persists, a renal biopsy may be considered, but bleeding risk and the need for general anesthesia limit its routine use.

Staging and Severity Assessment

Staging guides treatment intensity and prognostic communication. The IRIS AKI grading scheme, published by the International Renal Interest Society, uses serum creatinine and urine output to assign a grade from I to V. Grade I includes dogs with risk factors or suspected injury but no azotaemia. Grade II requires mild azotaemia with creatinine above the reference range but less than 1.6 times the upper limit. Grade III spans 1.6 to 2.5 times the upper limit, Grade IV from 2.5 to 5 times, and Grade V exceeds 5 times or requires renal replacement therapy. Each grade is further modified by urine output and the need for dialysis.

This staging framework does more than classify severity. It sets monitoring frequency and triggers for intervention. A Grade I patient may be managed with observation and serial biochemistry, while a Grade IV patient requires intensive care, continuous electrocardiographic monitoring for hyperkalemia, and preparation for renal replacement therapy. The staging grade should be recalculated at least every 24 hours because rapid progression is common in the first days after injury.

Monitoring Parameters and Their Interpretation

Serial monitoring detects deterioration before clinical decompensation. Serum creatinine and urine output form the core of monitoring, but electrolytes, acid-base status, and blood pressure provide the information needed to adjust therapy. The table below summarizes key parameters, their target ranges, and the clinical action each triggers.

Urine output is the most sensitive bedside indicator of renal perfusion and tubular function. A falling urine output in a volume-replete patient signals progressive injury and should prompt immediate reassessment of fluid balance, blood pressure, and cardiac output. Anuria, defined as urine output below 0.1 mL/kg/hour, carries a grave prognosis and usually indicates severe tubular necrosis or complete obstruction. Polyuria in the recovery phase may exceed 4 mL/kg/hour and requires careful matching of fluid losses to avoid dehydration.

Electrolyte monitoring detects life-threatening complications before they become symptomatic. Hyperkalemia is the most immediate threat because it causes cardiac arrhythmias and cardiac arrest. The electrocardiogram shows peaked T waves, widened QRS complexes, and loss of P waves as potassium rises. Hyperphosphataemia contributes to metastatic calcification and secondary renal hyperparathyroidism. Hypocalcemia may accompany hyperphosphataemia and requires correction before phosphate binders are used.

Fluid Therapy and Hemodynamic Support

Intravenous fluid therapy remains the foundation of AKI management, but the correct fluid choice and rate depend on the patient's volume status and the phase of injury. In the oliguric or anuric patient, aggressive fluid administration risks volume overload, pulmonary edema, and worsening hypertension. In the polyuric recovery phase, fluid requirements may be substantial and must be matched to measured losses.

Crystalloid solutions are the first-line choice. The selection between balanced electrolyte solutions and normal saline has clinical significance. Chloride-rich fluids such as normal saline may adversely affect renal function through their effect on renal blood flow and acid-base balance, as noted in the review of acute kidney injury in sepsis. Balanced solutions such as lactated Ringer's or Plasma-Lyte are preferred when hyperkalemia is not severe. Starch-containing colloids are nephrotoxic and should be avoided entirely in dogs with or at risk for AKI.

Fluid rate should be calculated from the patient's estimated deficit, ongoing losses, and maintenance requirements. A common approach is to replace the estimated deficit over 4 to 6 hours, then reassess. The goal is euvolaemia, not overhydration. Body weight, urine output, central venous pressure when available, and serial lung auscultation guide ongoing adjustments. In the oliguric patient, fluid rate should be reduced once euvolaemia is achieved, and further fluid administration should be justified by measurable losses.

Vasoactive drugs are indicated when hypotension persists despite adequate volume resuscitation. Norepinephrine is the dominant agent in human septic AKI, and vasopressin may have an adjunctive role, but the evidence base in dogs is limited and the choice of agent should be guided by blood pressure response and the underlying cause of hypotension, as discussed in the institutional review of septic acute kidney injury. Dobutamine may be considered when myocardial dysfunction is suspected. Blood pressure targets should be individualised, with a systolic pressure above 90 mmHg and a mean pressure above 65 mmHg as reasonable minimums.

Diuretics and Adjunctive Therapy

Loop diuretics such as furosemide are commonly used in oliguric AKI, but their role is to manage volume overload, not to treat the renal injury itself. No evidence demonstrates that diuretics improve survival or hasten renal recovery. They may convert an oliguric patient to nonoliguric, which simplifies fluid management, but this effect does not change the underlying disease course. Furosemide should be used only after volume status is optimized, and it should be discontinued if no diuretic response occurs within a few hours.

Mannitol has theoretical benefits including osmotic diuresis and free radical scavenging, but it is contraindicated in anuric patients and those with volume overload. Its use is limited to the early phase of injury when tubular obstruction is suspected. The evidence for benefit is weak, and the risk of pulmonary edema in anuric patients is substantial.

Urate-lowering therapy has been investigated in human AKI, particularly in tumor lysis syndrome, but its role in canine AKI is unclear. The National Kidney Foundation scientific workshop report notes that the relationship between uric acid and kidney disease remains controversial, with Mendelian randomisation studies generally not supporting a causal role. Routine measurement of uric acid in canine AKI is not currently recommended.

Nutritional Support and Gastrointestinal Protection

Protein restriction is not appropriate in the acute phase of AKI. Cats and dogs with AKI are catabolic, and protein restriction impairs immune function and delays tissue repair. The goal is to provide adequate protein to meet metabolic demands while limiting phosphorus intake. Commercial renal diets are often palatable and provide controlled phosphorus, but anorexic patients may require assisted feeding through a naso-esophageal or esophagostomy tube. Early enteral nutrition is associated with improved outcomes in critically ill patients across species.

Gastrointestinal ulceration is a recognized complication of uremia. Vomiting, hematemesis, and melaena indicate mucosal injury. Gastric protectants such as proton pump inhibitors are commonly used, and antiemetics such as maropitant or ondansetron improve food intake and quality of life. The choice of antiemetic should consider the drug's elimination pathway. Many drugs are renally cleared, and dosing intervals may need adjustment in azotaemic patients. Current formulary and label references must be consulted for specific dosing recommendations in renal impairment.

Documentation and Communication

Accurate documentation supports clinical decision-making and communication with owners. A flowsheet that records urine output, fluid input, body weight, blood pressure, and biochemistry at each assessment point allows rapid identification of trends. The IRIS AKI grade should be recorded at admission and updated daily. Photographs of urine sediment, when abnormal, provide a useful record for comparison.

Owner communication should address prognosis honestly. The review of acute kidney injury and its progression to chronic disease emphasizes that recovery from AKI is often incomplete and that residual structural damage predisposes to chronic kidney disease. Owners should understand that even dogs that survive the acute episode may develop progressive renal dysfunction months or years later. This expectation should be set early, and a recheck schedule should be established before discharge.

Recognized Complications and Failure Modes

Acute kidney injury in dogs follows a predictable set of complications that, when missed, convert reversible injury into irreversible loss of nephron mass. The most consequential is the transition from AKI to chronic kidney disease. Maladaptive repair mechanisms that persist after the acute phase promote inflammation and fibrosis, with growth-arrested tubular epithelial cells, macrophages, endothelium, and pericytes driving progression. Dogs that recover from an episode of AKI may retain subclinical structural damage that later manifests as CKD, and pre-existing CKD predisposes to more severe AKI. Detect this transition by persisting azotemia beyond 14 to 21 days, failure of urine concentrating ability to improve, and progressive proteinuria on serial urine protein to creatinine ratio measurements.

Oliguria or anuria that fails to respond to fluid resuscitation and diuretic challenge signals irreversible tubular necrosis or bilateral cortical necrosis. Detect it early by strict hourly urine output measurement in hospitalized dogs with indwelling urinary catheters. A urine output below 0.5 mL/kg/hour over six to eight hours despite adequate perfusion warrants immediate reassessment of volume status, blood pressure, and obstruction.

Hyperkalemia is the most immediately life-threatening metabolic complication. ECG changes, including peaked T waves, widened QRS complexes, and bradyarrhythmias, appear before serum potassium reaches critical thresholds. Serial electrolyte measurement every six to twelve hours in oliguric dogs is mandatory because potassium rises rapidly when urinary excretion ceases.

Uremic gastritis and gastrointestinal ulceration present as hematemesis, melaena, or worsening anemia. The combination of uremic toxins and stress-related mucosal injury makes this a common failure mode in hospitalized dogs. Detect it by monitoring packed cell volume trends, fecal occult blood, and clinical signs of vomiting.

Volume overload from overzealous fluid therapy is a frequent iatrogenic complication. It presents as progressive weight gain, serous nasal discharge, chemosis, pulmonary crackles, and eventually respiratory distress. Daily body weight measurement is the single most sensitive bedside indicator of positive fluid balance.

Common Clinical Errors and Corrective Actions

The most frequent error is treating the azotemia instead of the underlying process. Less experienced clinicians may initiate aggressive diuretic therapy before confirming volume status, which worsens prerenal azotemia in a dehydrated dog. Corrective action: always assess perfusion parameters, body weight, and urine output before administering diuretics.

A second error is under-recognizing the nephrotoxic potential of drugs used during hospitalization. Non-steroidal anti-inflammatory drugs, aminoglycosides, and contrast agents are all avoidable in dogs with suspected AKI. Review the complete drug list daily and discontinue any agent with renal elimination or nephrotoxic potential.

A third error is failing to distinguish AKI from decompensated CKD. Historical features, kidney size on ultrasound, and chronicity of clinical signs help separate these, but the distinction is not always possible at presentation. Management is similar initially, but prognosis and monitoring intensity differ substantially.

A fourth error is discharging dogs too early. Recovery from AKI can take weeks, and dogs that appear improved may still have concentrating defects or persistent azotemia. Discharge only when creatinine is stable or falling, urine output is normal, and the owner can reliably administer follow-up care.

Limitations of Current Evidence

The evidence base for canine AKI management is drawn substantially from human medicine and experimental models. Human data show that no therapeutic intervention other than dialysis reliably improves survival or speeds recovery. Whether this applies fully to dogs is uncertain, because canine AKI has different aetiologies and the veterinary literature contains few prospective randomised trials.

The pathophysiology of septic AKI remains poorly understood. Animal models suggest that early septic AKI may be a functional phenomenon with combined microvascular shunting and tubular cell stress, instead of overt tubular necrosis. This has therapeutic implications: aggressive fluid resuscitation may not reverse the functional component and may cause harm through volume overload.

The role of biomarkers in clinical decision-making remains contested. Cell cycle arrest biomarkers are gaining acceptance in human medicine, but their utility in dogs is not established. Urinary IL-18 has been implicated in AKI pathogenesis, and mitochondrial dysfunction with impaired mitophagy contributes to injury, but neither finding has translated into validated canine diagnostic tests. Expert opinion differs on whether biomarker panels should influence treatment decisions or remain research tools.

Referral, Consultation, and Reporting

Referral to a specialty hospital is warranted when a dog is oliguric or anuric despite twelve to twenty-four hours of appropriate fluid therapy, when hyperkalemia is refractory to medical management, when the clinician lacks the ability to perform continuous monitoring, or when renal replacement therapy may be required. Early referral is preferable to late referral because dogs with AKI deteriorate rapidly and transport becomes riskier as they become unstable.

Specialist consultation is appropriate for diagnostic uncertainty, particularly when the cause of AKI is unclear after initial investigation. A veterinary clinical pathologist can assist with interpretation of urine sediment, cytology, and atypical laboratory findings. A veterinary toxicologist may be helpful when exposure to an unidentified nephrotoxin is suspected.

Laboratory involvement extends beyond routine panels. Serial monitoring of electrolytes, acid-base status, and urine output requires a laboratory that can provide rapid turnaround. Confirm that the laboratory can perform urine protein to creatinine ratios, urine culture, and, where relevant, toxicology screens.

Regulatory reporting obligations vary by jurisdiction. Some causes of AKI, such as ethylene glycol intoxication, may have reporting requirements in certain regions. The AVMA practice resources provide guidance on professional obligations, while WOAH terrestrial animal health standards address reportable diseases that may present with renal manifestations. Clinicians should be familiar with their local requirements and report suspected notifiable diseases promptly.

Frequently Asked Questions

How Do I Manage AKI When Advanced Monitoring or 24-Hour Care Is Not Available?

Prioritize serial body weight, urine output estimation, and venous blood gas or biochemistry every 12 to 24 hours. If urine output cannot be measured, use absorbent pad weights and bladder palpation as crude surrogates. Fluid therapy should be delivered by infusion pump or counted drip sets, with recalculated rates at each reassessment. When blood pressure measurement is unavailable, use perfusion parameters such as mucous membrane color, capillary refill time, and mentation to guide fluid removal or escalation. Document every parameter in the record, because trends matter more than single values. Refer early if the patient deteriorates despite these measures, and be explicit with the owner about the limits of what can be achieved in that setting.

What Should I Tell an Owner Whose Dog Has Just Been Diagnosed With AKI?

Explain that the kidneys have sustained an acute insult and that recovery depends on the severity of injury, the underlying cause, and the response to supportive care over the first 48 to 72 hours. Avoid giving a confident prognosis at diagnosis. Describe the treatment plan in stages: stabilization, supportive therapy, and reassessment. Mention that hospitalization and intensive monitoring are usually required and that costs can escalate quickly. Be honest that some dogs do not recover and that progression to chronic kidney disease is possible even after apparent recovery, as noted in reviews of AKI as a springboard for chronic disease progression. Offer to discuss referral options if the caseload or facility cannot provide the required intensity of care.

How Does the Diagnostic Approach Differ in a Dog With Suspected Sepsis?

Septic AKI is the most common AKI syndrome in human intensive care and should be suspected in any dog with a septic focus, fever or hypothermia, and rising creatinine. The diagnosis rests on clinical assessment plus urine output and serum creatinine measurement, with the simultaneous presence of sepsis and AKI defining the syndrome. Resuscitation should target the sepsis itself, using judicious fluid therapy and vasoactive drugs as needed. Avoid starch-containing fluids, which are nephrotoxic, and consider whether chloride-rich crystalloids may adversely affect renal function. Urine output should be monitored hourly if a urinary catheter is in place, and perfusion parameters reassessed frequently because vasodilation and capillary leak alter fluid requirements.

What Is the Role of Uric Acid Measurement in Canine AKI?

Urate is an established cause of acute kidney injury in tumor lysis syndrome, and hyperuricemia is a recognized risk factor for kidney disease in humans, although the causal relationship remains debated. In dogs, uric acid measurement is most useful when leptospirosis, tumor lysis, or urate nephropathy is suspected. The evidence from human medicine shows that elevated serum urate may contribute to kidney disease through crystal-dependent and crystal-independent mechanisms, but Mendelian randomisation studies do not consistently support a causal role. Do not measure uric acid routinely in every AKI case. Reserve it for specific clinical contexts, and interpret elevations cautiously because even subtle reductions in glomerular filtration rate raise serum urate.

How Should I Document AKI Staging and Response to Therapy in the Medical Record?

Record the date and time of each creatinine and urine output measurement, the staging category assigned, and the criteria used to assign it. Note the suspected cause, the time of onset, and any inciting events such as anesthesia, NSAID exposure, or hypotension. Document fluid balance as input and output totals for each nursing shift, body weight at least twice daily, and blood pressure readings with cuff size and method. When therapy is changed, state the reason and the expected response. Use the same staging system consistently so that trends are visible across hospitalizations. This documentation supports clinical decisions, referral communication, and any future medicolegal review.

When Should I Recommend Euthanasia in a Dog With AKI That Is Not Improving?

Euthanasia is reasonable when the dog remains oliguric or anuric despite 48 to 72 hours of appropriate fluid therapy and supportive care, when complications such as severe uremic encephalopathy, refractory hyperkalemia, or disseminated intravascular coagulation develop, or when the owner cannot sustain the financial or emotional cost of continued hospitalization. The decision should be made jointly with the owner, using the documented trend in urine output, creatinine, and clinical status. If dialysis is available and the owner wishes to pursue it, referral should occur before the patient becomes unstable for transport. If dialysis is not an option, be clear that prolonged hospitalization without renal recovery has a poor prognosis.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Acute kidney injury in sepsis.. 2017.
• Acute Kidney Injury.. 2016.
• Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.. 2018.
• Acute kidney injury: a springboard for progression in chronic kidney disease.. 2010.
• Interleukin-18 and IL-18 binding protein.. 2013.
• Mitochondria ROS and mitophagy in acute kidney injury.. 2023.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Respiratory Virus: Diagnostic and Management Considerations
• Canine Vomiting: Diagnostic Approach and Management
• Canine Immune-Mediated Vasculitis: Clinical Recognition and Management
• Canine Acute Respiratory Distress Syndrome: Diagnostic Criteria and Management
• Canine Proteinuria: Diagnostic Approach and Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.